---
figid: PMC7017752__nihms-1065758-f0003
figtitle: Emerging therapeutic targets for neurofibromatosis type 1 (NF1)
organisms:
- NA
pmcid: PMC7017752
filename: nihms-1065758-f0003.jpg
figlink: pmc/articles/PMC7017752/figure/F3/
number: F3
caption: Plexiform neurofibromas (PNFs) develop from NF1+/− Schwann cells (SC) with
  a second hit resulting in NF1 biallelic inactivation (NF1−/−). These tumors comprise
  a mixture of SCs, mast cells, macrophages and fibroblasts intrinsic to the peripheral
  nerve. The growth of PNFs depends on the complex interplay between these cell types.
  KIT ligand is secreted by NF1−/− SCs and acts as a chemo-attractant for NF1+/− mast
  cells. In turn, NF1+/− mast cells produce TGFβ, stimulating NF1+/− fibroblasts to
  increase collagen production and other extracellular matrix (ECM) proteins. NF1+/−
  mast cells also produce heparin, vascular endothelial growth factor (VEGF) and matrix
  metalloproteinases (MMPs) promoting tumor vascularization and tumor invasiveness.
  NF1−/− SCs secrete colony-stimulating factor (CSF1) thereby recruiting macrophages,
  aiding tumor progression. Small molecule inhibitors in NF1 clinical trials are shown
  in red. Recent reports have highlighted the importance of inflammation, increased
  signaling through the WNT/β-catenin pathway and misregulated miRNAs in PNFs, all
  of which may represent potential therapeutic targets.
papertitle: Emerging therapeutic targets for neurofibromatosis type 1 (NF1).
reftext: James A. Walker, et al. Expert Opin Ther Targets. ;22(5):419-437.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9269298
figid_alias: PMC7017752__F3
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7017752__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7017752__nihms-1065758-f0003.html
  '@type': Dataset
  description: Plexiform neurofibromas (PNFs) develop from NF1+/− Schwann cells (SC)
    with a second hit resulting in NF1 biallelic inactivation (NF1−/−). These tumors
    comprise a mixture of SCs, mast cells, macrophages and fibroblasts intrinsic to
    the peripheral nerve. The growth of PNFs depends on the complex interplay between
    these cell types. KIT ligand is secreted by NF1−/− SCs and acts as a chemo-attractant
    for NF1+/− mast cells. In turn, NF1+/− mast cells produce TGFβ, stimulating NF1+/−
    fibroblasts to increase collagen production and other extracellular matrix (ECM)
    proteins. NF1+/− mast cells also produce heparin, vascular endothelial growth
    factor (VEGF) and matrix metalloproteinases (MMPs) promoting tumor vascularization
    and tumor invasiveness. NF1−/− SCs secrete colony-stimulating factor (CSF1) thereby
    recruiting macrophages, aiding tumor progression. Small molecule inhibitors in
    NF1 clinical trials are shown in red. Recent reports have highlighted the importance
    of inflammation, increased signaling through the WNT/β-catenin pathway and misregulated
    miRNAs in PNFs, all of which may represent potential therapeutic targets.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDGFRB
  - PDGFRA
  - NF1
  - KDR
  - FLT1
  - FLT4
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KIT
  - CSF1
  - SPACA9
  - SPG21
  - TGFB1
  - TGFB2
  - TGFB3
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - IFNK
  - IFNW1
  - IFNA1
  - IFNA2
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA17
  - IFNA21
  - IFNB1
  - CTNNB1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - Sunitinib
  - Sorafenib
  - Imatinib
  - Cabozantinib
  - Cediranib
  - Pirfenidone
---
